Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis

Brain

Volumn 128, Issue 5, 2005, Pages 988-1002

  Ishizu, Takaaki ^a   Osoegawa, Manabu ^a   Mei, Feng Jun ^a   Kikuchi, Hitoshi ^a   Tanaka, Masahito ^a   Takakura, Yuka ^a   Minohara, Motozumi ^a   Murai, Hiroyuki ^a   Mihara, Futoshi ^a   Taniwaki, Takayuki ^a   Kira, Jun Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cerebrospinal fluid; Chemokine; Cytokine; Multiple sclerosis; Neutrophil

Indexed keywords

ALBUMIN; CD4 ANTIGEN; CHEMOKINE; CYTOKINE; GADOLINIUM PENTETATE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CONVENTIONAL MULTIPLE SCLEROSIS; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTICOSPINAL MULTIPLE SCLEROSIS; PATHOLOGY; PRIORITY JOURNAL; SPINAL CORD; T LYMPHOCYTE; TH1 CELL;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-8; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; NEUTROPHIL INFILTRATION; SPINAL CORD;

EID: 21044448355     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh453     Document Type: Article

References (74)

1. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162: 1246-51.
2. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chera 2003; 278: 1910-4.
3. Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003; 112: 1186-91.
4. Comabella M, Imitola J, Weiner HL, Khoury SJ. Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol 2002; 126: 205-12.
5. Crée BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002; 22: 105-22.
6. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-8.
7. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-9.
8. Drulovic J, Mostarica-Stojkovic M, Levic Z, Stojsavljevic N, Pravica V, Mesaros S. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997; 147: 145-50.
9. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000; 59: 529-32.
10. Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Paulig A, et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998; 51: 753-8.
11. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-603.
12. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-8.
13. Genain CP, Hauser SL. Allergic encephalomyelitis in common marmosets: pathogenesis of a multiple sclerosis-like lesion. Methods 1996; 10: 420-34.
14. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-31.
15. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002; 72: 847-55.
16. Horiuchi I, Kawano Y, Yamasaki K, Minohara M, Furue M, Taniwaki T, et al. Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J Neurol Sci 2000; 172: 17-24.
17. Hoshino H, Laan M, Sjostrand M, Lotvall J, Skoogh BE, Linden A. Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J Allergy Clin Immunol 2000; 105: 143-9.
18. Huang WX, Huang P, Link H, Hillert J. Cytokine analysis in multiple sclerosis by competitive RT-PCR: a decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression. Mult Scler 1999; 5: 342-8.
19. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6: R120-8.
20. Ikuta F, Koga M, Takeda S, Ohama E, Takeshita I, Ogawa H, et al. Comparison of MS pathology between 70 American and 75 Japanese autopsy cases. In: Kuroiwa Y, Kurland LT, editors. Multiple sclerosis East and West. Fukuoka: Kyushu University Press; 1982. p. 298-306.
21. Jalonen TO, Pulkkinen K, Ukkonen M, Saarela M, Elovaara I. Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes. J Neurol 2002; 249: 576-83.
22. Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 2001; 45: 27-36.
23. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-27.
24. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40; 569-74.
25. Kleine TO, Zwerenz P, Graser C, Zofel P. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull 2003; 61: 327-6.
26. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
28. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162: 2347-52.
29. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997; 186: 307-12.
30. Laman JD, Thompson EJ, Kappos L. Balancing the Th1/Th2 concept in multiple sclerosis. Immunol Today 1998; 19: 489-90.
31. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004; 25: 132-7.
32. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.
33. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, et al. PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects. Biol Pharm Bull 2001; 24: 666-70.
34. Linden A. Role of interleukin-17 and the neutrophil in asthma. Int Arch Allergy Immunol 2001; 126: 179-84.
35. Linden A, Adachi M. Neutrophilic airway inflammation and IL-17. Allergy 2002; 57: 769-75.
36. Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998; 4: 12-5.
37. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol 1994; 36: 379-86.
38. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-8.
39. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-61.
40. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 498-502.
41. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-4.
42. Matusevicius D, Navikas V, Soderstrom M, Xiao BG, Haglund M, Fredrikson S, et al. Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996; 66: 115-23.
43. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
44. Minohara M, Ochi H, Matsushita S, Irie A, Nishimura Y, Kira J. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls. Tissue Antigens 2001; 57: 447-56.
45. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003; 48: 594-601.
46. Miyamoto M, Prause O, Sjostrand M, Laan M, Lotvall J, Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol 2003; 170: 4665-72.
47. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430-8.
48. Monteyne P, Van Laere V, Marichal R, Sindic CJ. Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: detection by RT-PCR without in vitro stimulation. J Neuroimmunol 1997; 80: 137-42.
49. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-33.
50. Navikas V, He B, Link J, Haglund M, Soderstrom M, Fredrikson S, et al. Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996; 119: 213-23.
51. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J Neurol Sci 2000; 179: 127-31.
52. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/ Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol 2001; 119: 297-305.
53. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995; 144: 245-68.
54. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5.
55. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44: 1523-6.
56. Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behcet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003; 145: 127-34.
57. Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002; 195: 41-6.
58. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-72.
59. Sharief MK, Thompson EJ. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 169-74.
60. Shiraki H. Neuropathological findings of demyelinating encephalomyelitides of unknown etiology in Japan. Saishin Igaku 1965; 20: 1036-52.
61. Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the 'resistant' Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999; 163: 40-9.
62. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-94.
63. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419-29.
64. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
65. Sørensen TL, Trebst C, Kivisakk P, Klaege KL, Majmudar A, Ravid R, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002; 127: 59-68.
66. Tabira T, Tateishi J. Neuropathological features of MS in Japan. In: Kuroiwa Y, Kurland LT, editors. Multiple sclerosis East and West. Fukuoka: Kyushu University Press; 1982. p. 273-95.
67. Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001; 58: 1975-80.
68. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695-703.
69. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243: 243-55.
70. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-14.
71. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567-79.
72. Wu XM, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Horiuchi I, et al. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci 2000; 177: 24-31.
73. Yamasaki K, Horiuchi I, Minohara M, Kawano Y, Ohyagi Y, Yamada T, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999; 122: 1689-96.
74. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164: 2832-8.